home All News open_in_new Full Article

Eli Lilly obesity pill disappoints in trial, sending shares down 14%

Weight loss comes in at lower end of expectations and triggers stock boost for rival Novo Nordisk


today 6 d. ago attach_file Politics

attach_file Economics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics


ID: 360351270
Add Watch Country

arrow_drop_down